28 results on '"Kato, Koji"'
Search Results
2. Risk factors for early death in neonates with Down syndrome and transient leukaemia.
- Author
-
Muramatsu, Hideki, Kato, Koji, Watanabe, Nobuhiro, Matsumoto, Kimikazu, Nakamura, Tomohiko, Horikoshi, Yasuo, Mimaya, Junichi, Suzuki, Chizuko, Hayakawa, Masahiro, and Kojima, Seiji
- Subjects
- *
DOWN syndrome , *LEUKEMIA , *LIVER failure , *CARDIOPULMONARY system , *DISEASES , *EARLY death , *PEDIATRICS education ,DIAGNOSIS of neonatal diseases - Abstract
Transient leukaemia (TL) in neonates with Down syndrome (DS) is characterized by the transient appearance of blast cells in the peripheral blood that resolves spontaneously. Some TL patients die at an early age due to organ failure. Seventy DS patients with TL were studied retrospectively to identify clinical and laboratory characteristics associated with early death (<6 months of age). Sixteen of 70 patients (22·9%) died early. The main causes of death were organ failure, particularly hepatic and cardiopulmonary failure. On univariate analysis, early gestational age (EGA), high white blood cell (WBC) count (≥100 × 109/l), percentage of peripheral blasts, elevated aspartate transaminase (AST), elevated direct bilirubin (DB), and low Apgar score were significantly associated with poor survival. On multivariate analysis, EGA, WBC count, and DB were independent predictors of poor outcome. A simple risk stratification system combining EGA and WBC count was devised to predict poor outcome. Term infants (EGA ≥ 37 weeks) whose WBC count was lower than 100 × 109/l had the best outcome [7·7% (3/39) died early], while preterm infants (EGA < 37 weeks) whose WBC count was higher than 100 × 109/l had the worst outcome [54·5% (6/11) died early]. This stratification system may be useful for identifying high-risk patients who need early therapeutic interventions. [ABSTRACT FROM AUTHOR]
- Published
- 2008
- Full Text
- View/download PDF
3. The Japanese cord blood bank network experience with cord blood transplantation from unrelated donors for haematological malignancies: an evaluation of graft-versus-host disease prophylaxis.
- Author
-
Nishihira, Hirokazu, Kato, Koji, Isoyama, Keiichi, Takahashi, Tsuneo A., Kai, Shunro, Kato, Shunichi, Takanashi, Minoko, Sato, Norihiro, Sato, Hiroyuki, Kitajima, Kohichi, Naoe, Tomoki, and Saito, Hidehiko
- Subjects
- *
CORD blood transplantation , *GRAFT versus host disease , *HEMATOLOGY - Abstract
Summary. Cryopreserved umbilical cord blood (CB) from unrelated donors can restore haematopoiesis after myeloablative therapy in patients with haematological malignancy. We investigated the clinical outcomes of CB transplantation (CBT) with special emphasis on graft-versus-host disease (GVHD) prophylaxis. Patients with haematological malignancies (n = 216) received intensive chemotherapy or immunosuppressive therapy, followed by transplantation of cryopreserved CB cells from unrelated donors. The clinical outcomes, i.e. haematological reconstitution, the incidence of acute or chronic GVHD, relapse and event-free survival (EFS), were evaluated. The estimated probability of neutrophil recovery was 88·2%. The median follow-up for the survivors was 557 d (range 21–1492 d). The overall and EFS rates were 32·6% and 25·5%, respectively, 3·5 years after transplantation. Multivariate analysis using Cox's proportional hazards model showed that high-risk disease status at CBT and single-drug GVHD prophylaxis were associated with worse 2-year EFS rates [P = 0·0013, relative risk (RR) 1·90, 95% confidence interval (CI) 1·28–2·81 and P = 0·0007, RR 1·91, 95% CI 1·31–2·79 respectively). Age at CBT had no significant influence on EFS. Cryopreserved CB from unrelated donors can restore haematopoiesis in patients with haematological malignancy. Although the incidence is low, the prophylaxis for acute GVHD is an important factor for survival of CBT from unrelated donors. A high rate of suitable donors was found, with a probability of 1 to every 18 CB units, when compared with human leucocyte antigen matching at other haematopoietic stem cell banks. [ABSTRACT FROM AUTHOR]
- Published
- 2003
- Full Text
- View/download PDF
4. Impact of asparaginase discontinuation on outcomes of children with acute lymphoblastic leukaemia receiving the Japan Association of Childhood Leukaemia Study ALL‐02 protocol.
- Author
-
Ishida, Hisashi, Imamura, Toshihiko, Tatebe, Yasuhisa, Ishihara, Takashi, Sakaguchi, Kimiyoshi, Suenobu, Souichi, Sato, Atsushi, Hashii, Yoshiko, Deguchi, Takao, Takahashi, Yoshihiro, Hasegawa, Daiichiro, Miyamura, Takako, Iguchi, Akihiro, Kato, Koji, Saito‐Moriya, Akiko, Hara, Junichi, and Horibe, Keizo
- Subjects
- *
LYMPHOBLASTIC leukemia , *ACUTE leukemia , *ASPARAGINASE , *LEUKEMIA , *PROGNOSIS - Abstract
Summary: Asparaginase is an essential drug for acute lymphoblastic leukaemia (ALL) treatment, but has several side effects, and its discontinuation often compromises patient outcomes. In the prospective Japan Association of Childhood Leukaemia Study ALL‐02 protocol, two major changes were made: (1) additional chemotherapies to compensate for the reduction of treatment intensity when asparaginase was discontinued and (2) more intensive concomitant corticosteroid administration, relative to our previous ALL‐97 protocol. In ALL‐02 study, 1192 patients were included and L‐asparaginase was discontinued for 88 (7.4%). Discontinuation due to allergy was markedly decreased relative to the ALL‐97 protocol (2.3% vs 15.4%). Event‐free survival (EFS) among patients with T‐ALL was compromised when L‐asparaginase was discontinued, as well as among patients with high‐risk B‐cell ALL, especially when discontinued before maintenance therapy. Moreover, multivariate analysis identified discontinuation of L‐asparaginase as an independent poor prognostic factor for EFS. In the current study, additional chemotherapies failed to fully compensate for L‐asparaginase discontinuation, illustrating the difficulty of replacing asparaginase with other classes of drugs, although this study was not designed to evaluate the effect of these modifications. Concomitant intensive corticosteroid treatment may help to reduce allergy to asparaginase. These results will assist in further optimization of asparaginase use. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
5. Haematopoietic cell transplantation for children with acute megakaryoblastic leukaemia without Down syndrome.
- Author
-
Hama, Asahito, Taga, Takashi, Tomizawa, Daisuke, Muramatsu, Hideki, Hasegawa, Daiichiro, Adachi, Souichi, Yoshida, Nao, Noguchi, Maiko, Sato, Maho, Okada, Keiko, Koh, Katsuyoshi, Mitsui, Tetsuo, Takahashi, Yoshiyuki, Miyamura, Takako, Hashii, Yoshiko, Kato, Koji, Atsuta, Yoshiko, and Okamoto, Yasuhiro
- Subjects
- *
CELL transplantation , *ACUTE leukemia , *DOWN syndrome , *HLA histocompatibility antigens , *PATIENTS' attitudes - Abstract
Summary: Patients with acute megakaryoblastic leukaemia of Down syndrome (DS‐AMKL) have an excellent survival rate; however, patients with non‐DS‐AMKL experience poor outcomes. Therefore, this study retrospectively analysed 203 children with non‐DS‐AMKL who underwent their first haematopoietic cell transplantation (HCT) from 1986 to 2015 using a nationwide Japanese HCT registry data to assess HCT outcomes for non‐DS‐AMKL. The 5‐year overall survival (OS) and event‐free survival (EFS) rates were 43% and 38% respectively. The 5‐year OS rate was significantly higher for patients who underwent HCT in the first complete remission (CR1, 72%) than for those in the second CR (CR2, 23%) and non‐CR (16%) (p < 0.001), and for those from a human leukocyte antigen (HLA)‐matched (52%) than for those from an HLA‐mismatched donor (27%) (p < 0.001). Multivariate analysis for OS revealed that HCT in CR2 and non‐CR was a significant risk factor (hazard ratio, 5.86; 95% confidence interval, 3.56–9.53; p < 0.001). The 3‐year EFS in patients who received HCT in CR1 using reduced‐intensity conditioning (RIC, 35%) was significantly lower than in those using myeloablative conditioning (busulfan‐based, 71%; total body irradiation‐based, 58%) (p < 0.001). Risk stratification in patients with non‐DS‐AMKL should be established to determine HCT indication in CR1. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
6. Comparison of transplant outcomes between haploidentical transplantation and single cord blood transplantation in non‐remission acute myeloid leukaemia: A nationwide retrospective study.
- Author
-
Matsuda, Kensuke, Konuma, Takaaki, Fuse, Kyoko, Masuko, Masayoshi, Kawamura, Koji, Hirayama, Masahiro, Uchida, Naoyuki, Ikegame, Kazuhiro, Wake, Atsushi, Eto, Tetsuya, Doki, Noriko, Miyakoshi, Shigesaburo, Tanaka, Masatsugu, Takahashi, Satoshi, Onizuka, Makoto, Kato, Koji, Kimura, Takafumi, Ichinohe, Tatsuo, Takayama, Nobuyuki, and Kobayashi, Hikaru
- Subjects
- *
CORD blood transplantation , *ACUTE myeloid leukemia , *HEMATOPOIETIC stem cell transplantation , *TREATMENT effectiveness , *PROPENSITY score matching - Abstract
Summary: Allogeneic haematopoietic stem cell transplantation (HSCT) is a potentially curative treatment for some patients with acute myeloid leukaemia (AML) who are refractory to chemotherapy. Cord blood transplantation (CBT) is a reasonable option in such cases because of its rapid availability. Recently, a growing number of human leucocyte antigen (HLA)‐haploidentical related donor HSCTs (haplo‐HSCTs) have been performed, although its effectiveness remains undetermined. Using the Japanese nationwide transplantation registry data, we identified 2438 patients aged ≥16 years who received CBT or haplo‐HSCT as their first transplant for non‐remission AML between January 2008 and December 2018. After 2:1 propensity score matching, 918 patients in the CBT group and 459 patients in the haplo‐HSCT group were selected. In this matched cohort, no significant difference in overall survival (OS) was observed between the CBT and haplo‐HSCT groups (hazard ratio [HR] of haplo‐HSCT to CBT 1.02, 95% confidence interval [CI] 0.89–1.16). Similarly, no significant difference in the cumulative incidence of relapse (HR 1.09, 95% CI 0.93–1.28) or non‐relapse mortality (HR 0.94, 95% CI 0.76–1.18). Subgroup analysis showed that CBT was significantly associated with preferable OS in patients receiving myeloablative conditioning. Our data showed comparable outcomes between haplo‐HSCT and CBT recipients with non‐remission AML. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
7. Could the minimum number of haematopoietic stem cells to obtain engraftment exist in unrelated, single cord blood transplantation?
- Author
-
Yabe, Hiromasa, Tabuchi, Ken, Uchida, Naoyuki, Takahashi, Satoshi, Onishi, Yasushi, Aotsuka, Nobuyuki, Sugio, Yasuhiro, Ikegame, Kazuhiro, Ichinohe, Tatsuo, Takahashi, Minoko, Kato, Koji, Atsuta, Yoshiko, and Kanda, Yoshinobu
- Subjects
- *
CORD blood transplantation , *STEM cells - Published
- 2020
- Full Text
- View/download PDF
8. Which is more important for the selection of cord blood units for haematopoietic cell transplantation: the number of CD34‐positive cells or total nucleated cells?
- Author
-
Nakasone, Hideki, Tabuchi, Ken, Uchida, Naoyuki, Ohno, Yuju, Matsuhashi, Yoshiko, Takahashi, Satoshi, Onishi, Yasushi, Onizuka, Makoto, Kobayashi, Hikaru, Fukuda, Takahiro, Ichinohe, Tatsuo, Takanashi, Minoko, Kato, Koji, Atsuta, Yoshiko, Yabe, Hiromasa, and Kanda, Yoshinobu
- Abstract
The article discusses the study which identifies whether CD34-positive cells or total nucleated cells is the important method for the selection of cord blood units for haematopoietic cell transplantation. It states that cell doses should be considered when selecting cord blood units for transplantation as well as human leucocyte antigen matching.
- Published
- 2019
- Full Text
- View/download PDF
9. Follow‐up of a randomised phase II study of chemotherapy alone or in combination with mogamulizumab in newly diagnosed aggressive adult T‐cell leukaemia‐lymphoma: impact on allogeneic haematopoietic stem cell transplantation.
- Author
-
Ishida, Takashi, Jo, Tatsuro, Takemoto, Shigeki, Suzushima, Hitoshi, Suehiro, Youko, Choi, Ilseung, Yoshimitsu, Makoto, Saburi, Yoshio, Nosaka, Kisato, Utsunomiya, Atae, Kobayashi, Yukio, Yamamoto, Kazuhito, Fujiwara, Hiroshi, Ishitsuka, Kenji, Yoshida, Shinichiro, Taira, Naoya, Imada, Kazunori, Kato, Koji, Moriuchi, Yukiyoshi, and Yoshimura, Kenichi
- Abstract
The article informs on a phase II study conducted for evaluating whether the addition of mogamulizumab, a defucosylated humanised anti-CCR4 antibody, to mLSG15 increases efficacy in patients with newly-diagnosed aggressive adult T cell leukaemia-lymphoma (ATL). It examines its impact on allogeneic haematopoietic stem cell transplantation; and no differences were found in the survival between the mLSG15+mogamulizumab and mLSG15 arms in patients with newly diagnosed aggressive ATL.
- Published
- 2019
- Full Text
- View/download PDF
10. Clinical significance of SH2B3 (LNK) expression in paediatric B‐cell precursor acute lymphoblastic leukaemia.
- Author
-
Yano, Mio, Imamura, Toshihiko, Asai, Daisuke, Deguchi, Takao, Hashii, Yoshiko, Endo, Mikiya, Sato, Atsushi, Kawasaki, Hirohide, Kosaka, Yoshiyuki, Kato, Koji, Hori, Hiroki, Yumura‐Yagi, Keiko, Hara, Junichi, Oda, Megumi, and Horibe, Keizo
- Subjects
- *
LYMPHOBLASTIC leukemia , *ADAPTOR proteins , *B cells , *PROTEIN expression , *MESSENGER RNA , *DELETION mutation - Abstract
The article discusses a study focusing on paediatric B-cell precursor acute lymphoblastic leukaemia (B-ALL) and clinical significance of adaptor protein SH2B3 (LNK) expression in it. Topics discussed include the determination of SH2B3 mRNA expression level in the study; the frequency of IKZF1 deletion in the patients under study; and the rate of event-free survival (EFS) in patients under study.
- Published
- 2018
- Full Text
- View/download PDF
11. Comparative analysis of pulmonary hypertension in patients treated with imatinib, nilotinib and dasatinib.
- Author
-
Minami, Mariko, Arita, Takeshi, Iwasaki, Hiromi, Muta, Tsuyoshi, Aoki, Takatoshi, Aoki, Kenichi, Yamasaki, Satoshi, Matsushima, Takamitsu, Kato, Koji, Takenaka, Katsuto, Tanimoto, Kazuki, Kamimura, Tomohiko, Ogawa, Ryosuke, Akashi, Koichi, and Miyamoto, Toshihiro
- Subjects
- *
PULMONARY hypertension , *IMATINIB , *NILOTINIB , *DASATINIB , *ADVERSE health care events - Abstract
Pulmonary hypertension (PH) is a rare, but life-threatening, adverse event in patients treated with tyrosine kinase inhibitors (TKIs), such as dasatinib, but has not been fully evaluated in patients treated with imatinib or nilotinib. We used echocardiography to noninvasively assess the incidence of PH in 105 patients with chronic myeloid leukaemia (CML) treated with imatinib ( n = 37), nilotinib ( n = 30) or dasatinib ( n = 38). The mean triscupid regurgitation peak gradient (TRPG), which reflects pulmonary arterial pressure, was 22·7 mmHg in the imatinib group, 23·1 mmHg in the nilotinib group and 23·4 mmHg for dasatinib group. These values were not significantly different, but higher than those (19·0 mmHg) in newly diagnosed CML patients. A TRPG > 31 mmHg, marking possible PH onset, was detected in 9 of 105 patients: one (2·7%) treated with imatinib, three (10·0%) with nilotinib and five (13·2%) with dasatinib. Only three patients complained of dyspnoea, whereas the other six were asymptomatic. In addition, there was a tendency toward correlation of TRPG value and age or TKI treatment duration. These results suggested that treatment with not only dasatinib, but also imatinib and nilotinib, can be associated with subclinical PH. Noninvasive echocardiography is useful for screening, especially in older patients with long-term TKI treatment. [ABSTRACT FROM AUTHOR]
- Published
- 2017
- Full Text
- View/download PDF
12. Clinical utility of next-generation sequencing-based minimal residual disease in paediatric B-cell acute lymphoblastic leukaemia.
- Author
-
Sekiya, Yuko, Xu, Yinyan, Muramatsu, Hideki, Okuno, Yusuke, Narita, Atsushi, Suzuki, Kyogo, Wang, Xinan, Kawashima, Nozomu, Sakaguchi, Hirotoshi, Yoshida, Nao, Hama, Asahito, Takahashi, Yoshiyuki, Kato, Koji, and Kojima, Seiji
- Subjects
- *
LYMPHOBLASTIC leukemia in children , *NUCLEOTIDE sequencing , *B cells , *PROPORTIONAL hazards models , *DISEASES ,BONE marrow examination - Abstract
We assessed the clinical utility of next-generation sequencing ( NGS)-based monitoring of minimal residual disease ( MRD) in a uniformly treated cohort of 79 patients with paediatric B-cell acute lymphoblastic leukaemia. Bone marrow samples were collected at the time of diagnosis, days 33 and 80, pre- (4-5 months) and post- (24 months) maintenance therapy time points, and at relapse. We identified leukaemia-specific CDR3 sequences in 72 of 79 patients (91%) and detected MRD in 59 of 232 samples. Although MRD was detected in 28 of 55 samples (51%) on day 33, the frequencies of MRD detection decreased to 25% (16/65) at day 80, 19% (11/58) at 4-5 months and 7·4% (4/54) at 24 months. In a univariate analysis, positive MRD results on day 80 [relative risk (RR) 95% confidence interval (CI) = 7·438 (2·561-21·6), P < 0·001], at 4-5 months [ RR (95% CI) = 10·24 (3·374-31·06), P < 0·001], and at 24 months [ RR (95% CI) = 19·26 (4·974-74·59), P < 0·001] exhibited statistically significant associations with inferior leukaemia-free survival; this was confirmed using a Cox proportional hazard model. Our study suggests the promising potential of NGS- MRD for patients with B-cell ALL. [ABSTRACT FROM AUTHOR]
- Published
- 2017
- Full Text
- View/download PDF
13. Identification of novel kinase fusion transcripts in paediatric B cell precursor acute lymphoblastic leukaemia with IKZF1 deletion.
- Author
-
Yano, Mio, Imamura, Toshihiko, Asai, Daisuke, Kiyokawa, Nobutaka, Nakabayashi, Kazuhiko, Matsumoto, Kenji, Deguchi, Takao, Hashii, Yoshiko, Honda, Yu‐ko, Hasegawa, Daiichiro, Sasahara, Yoji, Ishii, Mutsuo, Kosaka, Yoshiyuki, Kato, Koji, Shima, Midori, Hori, Hiroki, Yumura‐Yagi, Keiko, Hara, Junichi, Oda, Megumi, and Horibe, Keizo
- Subjects
- *
LYMPHOBLASTIC leukemia treatment , *CYTOKINE receptors , *JANUS kinases , *DELETION mutation , *TARGETED drug delivery , *BLOOD cell count - Abstract
Activating tyrosine kinase mutations or cytokine receptor signalling alterations have attracted attention as therapeutic targets for high-risk paediatric acute lymphoblastic leukaemia (ALL). We identified two novel kinase fusions, OFD1-JAK2 and NCOR1-LYN, in paediatric ALL patients with IKZF1 deletion, by mRNA sequencing. The patient with CSF2RA-CRLF2 also harboured IGH-EPOR. All these patients had high-risk features, such as high initial white blood cell counts and initial poor response to prednisolone. The functional analysis of these novel fusions is on-going to determine whether these genetic alterations can be targeted by drugs. [ABSTRACT FROM AUTHOR]
- Published
- 2015
- Full Text
- View/download PDF
14. Allogeneic haematopoietic stem cell transplantation for infant acute lymphoblastic leukaemia with KMT2A ( MLL) rearrangements: a retrospective study from the paediatric acute lymphoblastic leukaemia working group of the Japan Society for Haematopoietic Cell Transplantation
- Author
-
Kato, Motohiro, Hasegawa, Daiichiro, Koh, Katsuyoshi, Kato, Keisuke, Takita, Junko, Inagaki, Jiro, Yabe, Hiromasa, Goto, Hiroaki, Adachi, Souichi, Hayakawa, Akira, Takeshita, Yasufumi, Sawada, Akihisa, Atsuta, Yoshiko, and Kato, Koji
- Subjects
- *
HEMATOPOIETIC stem cell transplantation , *LYMPHOBLASTIC leukemia in children , *TOTAL body irradiation , *BUSULFAN , *CANCER remission - Abstract
Allogeneic haematopoietic stem cell transplantation ( HSCT) is still considered to play an important role as a consolidation therapy for high-risk infants with acute lymphoblastic leukaemia ( ALL). Here, we retrospectively analysed outcomes of HSCT in infants with ALL based on nationwide registry data of the Japan Society for Haematopoietic Cell Transplantation. A total of 132 allogeneic HSCT for infant ALL with KMT2A ( MLL) gene rearrangements, which were performed in first complete remission ( CR1), were analysed. The 5-year overall survival rate after transplantation was 67·4 ± 4·5%). Although recent HSCT (after 2004) had a trend toward better survival, no statistical correlation was observed between outcomes and each factor, including age at diagnosis, initial leucocyte count, cytogenetics, donor types or conditioning of HSCT. Myeloablative conditioning with total body irradiation did not provide a better survival (60·7 ± 9·2%) over that with busulfan ( BU; 67·8 ± 5·7%). Two of the 28 patients treated with irradiation, but none of the 90 BU-treated patients, developed a secondary malignant neoplasm. In conclusion, allogeneic HSCT using BU was a valuable option for infant ALL with KMT2A rearrangements in CR1. [ABSTRACT FROM AUTHOR]
- Published
- 2015
- Full Text
- View/download PDF
15. Haematopoietic stem cell transplantation for relapsed or refractory anaplastic large cell lymphoma: a study of children and adolescents in Japan.
- Author
-
Fukano, Reiji, Mori, Tetsuya, Kobayashi, Ryoji, Mitsui, Tetsuo, Fujita, Naoto, Iwasaki, Fuminori, Suzumiya, Junji, Chin, Motoaki, Goto, Hiroaki, Takahashi, Yoshiyuki, Hara, Junichi, Park, Yong‐Dong, Inoue, Masami, Koga, Yuhki, Inagaki, Jiro, Sakamaki, Hisashi, Adachi, Souichi, Kawa, Keisei, Kato, Koji, and Suzuki, Ritsuro
- Subjects
- *
HEMATOPOIETIC stem cell transplantation , *T-cell lymphoma , *LYMPHOMAS in children , *CANCER relapse , *CANCER remission , *PROGRESSION-free survival - Abstract
To evaluate haematopoietic stem cell transplantation ( HSCT) in children and adolescents, we reviewed the records of 47 patients who were ≤18 years, had relapsed or refractory anaplastic large cell lymphoma, and received HSCT between 1990 and 2010. At HSCT, complete remission ( CR) was less common in allogeneic HSCT recipients ( n = 24) than in autologous HSCT recipients ( n = 23) ( P = 0·01). The autologous and allogeneic HSCT groups differed in terms of 5-year event-free survival ( EFS) (38% vs. 50%, P = 0·63), cumulative incidence of progress or relapse (49% vs. 28%, P = 0·25), and treatment-related mortality (12% vs. 25%, P = 0·40). However, these differences were not significant. Patients with non- CR at autologous HSCT had a significantly lower EFS rate (14% vs. 48%, P = 0·03). Conversely, although those with non- CR at allogeneic HSCT had a lower EFS rate, this was not significant (44% vs. 63%, P = 0·26). Reduced-intensity conditioning regimens were used for three of the 16 allogeneic HSCTs received by patients with non- CR. These three patients achieved CR, surviving 32-65 months after HSCT. These results demonstrated that allogeneic HSCT might be a treatment option for patients who do not achieve CR through conventional chemotherapy. [ABSTRACT FROM AUTHOR]
- Published
- 2015
- Full Text
- View/download PDF
16. Outcome in 146 patients with paediatric acute myeloid leukaemia treated according to the AML99 protocol in the period 2003-06 from the Japan Association of Childhood Leukaemia Study.
- Author
-
Imamura, Toshihiko, Iwamoto, Shotaro, Kanai, Rie, Shimada, Akira, Terui, Kiminori, Osugi, Yuko, Kobayashi, Ryoji, Tawa, Akio, Kosaka, Yoshiyuki, Kato, Koji, Hori, Hiroki, Horibe, Keizo, Oda, Megumi, and Adachi, Souichi
- Subjects
- *
ACUTE myeloid leukemia in children , *STEM cell transplantation , *HEALTH outcome assessment , *MEDICAL statistics , *CLINICAL trials , *LEUKEMIA treatment - Abstract
The acute myeloid leukaemia ( AML) 99 trial conducted previously in Japan for the treatment of de novo paediatric AML showed excellent results, with a 5-year overall survival ( OS) and event-free survival ( EFS) of 75·6% and 61·6%, respectively. To examine reproducibility of these results in another cohort, the outcome of 146 newly diagnosed AML paediatric patients prospectively registered in the Japan Association of Childhood Leukaemia Study ( JACLS) from 2003 to 2006 was compared to that of 240 patients in the original AML 99 clinical trial. The 5-year EFS and OS achieved in the new cohort was 66·7 ± 4·0% and 77·7 ± 8·0% respectively, which were comparable to those obtained in the original AML 99 clinical trial, although less frequent core-binding factor ( CBF) AML (29·5% vs. 37%) and an almost equal frequency of allogeneic haematopoietic stem cell transplantation (allo- HSCT) during first complete remission (16·5% vs. 19%) were observed. The 5-year EFS in patients with a normal karyotype ( NK) ( n = 35, 54·9 ± 15·1%) was inferior in the present cohort when compared to the original AML99 trial. This study confirmed the excellent outcome of the original AML99 protocol. [ABSTRACT FROM AUTHOR]
- Published
- 2012
- Full Text
- View/download PDF
17. Stem cell transplantation for paediatric patients with non-anaplastic peripheral T-cell lymphoma in Japan.
- Author
-
Kobayashi, Ryoji, Fujita, Naoto, Mitsui, Tetsuo, Iwasaki, Fuminori, Suzumiya, Junji, Kuroda, Hiroshi, Nishimura, Ryosei, Sasahara, Youji, Takeshita, Yasushi, Kato, Keisuke, Okumura, Hirokazu, Sakamaki, Hisashi, Yabe, Hiromasa, Kawa, Keisei, Kato, Koji, and Suzuki, Ritsuro
- Subjects
- *
STEM cell transplantation , *PEDIATRICS , *T-cell lymphoma , *DISEASE relapse , *GRAFT versus host disease , *PATIENTS - Abstract
Reports of non-anaplastic peripheral T-cell lymphoma ( PTCL) in paediatric patients, especially results of stem cell transplantation ( SCT), are relatively rare. We herein report the results of SCT using the Transplant Registry Unified Management Program system of the Japanese Society of Stem Cell Transplantation in paediatric patients with non-anaplastic PTCL. We analysed 26 patients (13 females and 13 males) aged ≤18 years with non-anaplastic PTCL who underwent a total of 28 SCT. Median age at transplantation was 13·5 years (range: 0-18 years). PTCL not otherwise specified was diagnosed in 17 patients; extranodal Natural Killer ( NK)/ T cell lymphoma, nasal type in nine; and subcutaneous panniculitis-like T-cell lymphoma in two. Transplantation was with syngeneic donor in one, related donor in 10; unrelated donor in 10; and auto transplantation in 7. Five-year overall survival rate and event-free survival rate was 62·96% and 55·56%, respectively. Male gender, chronic graft- versus-host disease ( GVHD), and reduced intensity conditioning were good prognostic factors in all patients. In 20 patients with refractory or relapsed disease, male gender and chronic GVHD were also good prognostic factors. This study is the first report concerning transplantation in children with non-anaplastic PTCL, although the number of patients was small. Larger studies are needed to confirm these findings. [ABSTRACT FROM AUTHOR]
- Published
- 2012
- Full Text
- View/download PDF
18. Molecular lesions in childhood and adult acute megakaryoblastic leukaemia.
- Author
-
Hama, Asahito, Muramatsu, Hideki, Makishima, Hideki, Sugimoto, Yuka, Szpurka, Hadrian, Jasek, Monika, O'Keefe, Christine, Takahashi, Yoshiyuki, Sakaguchi, Hirotoshi, Doisaki, Sayoko, Shimada, Akira, Watanabe, Nobuhiro, Kato, Koji, Kiyoi, Hitoshi, Naoe, Tomoki, Kojima, Seiji, and Maciejewski, Jaroslaw P.
- Subjects
- *
LEUKEMIA , *DOWN syndrome , *SINGLE nucleotide polymorphisms , *CHROMOSOMES , *GENETIC mutation , *PEDIATRICS - Abstract
Summary While acute megakaryoblastic leukaemia (AMKL) occurs in children with (DS-AMKL) and without (paediatric non-DS-AMKL) Down syndrome, it can also affect adults without DS (adult non-DS-AMKL). We have analysed these subgroups of patients (11 children with DS-AMKL, 12 children and four adults with non-DS-AMKL) for the presence of molecular lesions, including mutations and chromosomal abnormalities studied by sequencing and single nucleotide polymorphism array-based karyotyping, respectively. In children, AMKL was associated with trisomy 21 (somatic in non-DS-AMKL), while numerical aberrations of chromosome 21 were only rarely associated with adult AMKL. DS-AMKL was also associated with recurrent somatic gains of 1q (4/11 DS-AMKL patients). In contrast to trisomy 21 and gains of 1q, other additional chromosomal lesions were evenly distributed between children and adults with AMKL. A mutational screen found GATA1 mutations in 11/12 DS-AMKL, but mutations were rare in paediatric non-DS-AMKL (1/12) and adult AMKL (0/4). JAK3 (1/11), JAK2 (1/11), and TP53 mutations (1/11) were found only in patients with DS-AMKL. ASXL1, IDH1/2, DNMT3A, RUNX1 and CBL mutations were not found in any of the patient group studied, while NRAS mutation was identified in two patients with paediatric non-DS-AMKL. [ABSTRACT FROM AUTHOR]
- Published
- 2012
- Full Text
- View/download PDF
19. Outcome of unrelated umbilical cord blood transplantation in 88 patients with primary immunodeficiency in Japan.
- Author
-
Morio, Tomohiro, Atsuta, Yoshiko, Tomizawa, Daisuke, Nagamura-Inoue, Tokiko, Kato, Koji, Ariga, Tadashi, Kawa, Keisei, Koike, Kazutoshi, Tauchi, Hisamichi, Kajiwara, Michiko, Hara, Toshiro, and Kato, Shunichi
- Subjects
- *
UMBILICAL cord , *CORD blood transplantation , *IMMUNODEFICIENCY , *WISKOTT-Aldrich syndrome , *NEUTROPENIA , *MULTIVARIATE analysis , *COMPLICATIONS from organ transplantation , *PATIENTS , *SURGERY - Abstract
Summary [ABSTRACT FROM AUTHOR]
- Published
- 2011
- Full Text
- View/download PDF
20. Spectrum of molecular defects in juvenile myelomonocytic leukaemia includes ASXL1 mutations.
- Author
-
Sugimoto, Yuka, Muramatsu, Hideki, Makishima, Hideki, Prince, Courtney, Jankowska, Anna M., Yoshida, Nao, Yinyan Xu, Nishio, Nobuhiro, Hama, Asahito, Yagasaki, Hiroshi, Takahashi, Yoshiyuki, Kato, Koji, Manabe, Atsushi, Kojima, Seiji, and Maciejewski, Jaroslaw P.
- Subjects
- *
LEUKEMIA in children , *MOLECULAR diagnosis , *MYELOPROLIFERATIVE neoplasms , *MYELOID leukemia , *REPRESSION (Psychology) in children - Abstract
Mutations in NF1, PTPN11, NRAS, KRAS and CBL have been reported to play a pathogenetic role in juvenile myelomonocytic leukaemia (JMML), a rare myelodyplastic/myeloproliferative neoplasm occurring in children. Recently, mutations in ASXL1 were identified in chronic myelomonocytic leukaemia and other myeloid malignancies. We sequenced exon 12 of ASLX1 in 49 JMML patients, and found 2 novel heterozygous (nonsense and frameshift) mutations, one occurring as a sole lesion, the other was in conjunction with a PTPN11 mutation. ASXL1 cooperates with KDM1A in transcriptional repression and thereby ASXL1 mutations may synergize with or mimic other JMML-related mutations. [ABSTRACT FROM AUTHOR]
- Published
- 2010
- Full Text
- View/download PDF
21. Acute megakaryoblastic leukaemia (AMKL) in children: a comparison of AMKL with and without Down syndrome.
- Author
-
Hama, Asahito, Yagasaki, Hiroshi, Takahashi, Yoshiyuki, Nishio, Nobuhiro, Muramatsu, Hideki, Yoshida, Nao, Tanaka, Makito, Hidaka, Hirokazu, Watanabe, Nobuhiro, Yoshimi, Ayami, Matsumoto, Kimikazu, Kudo, Kazuko, Kato, Koji, Horibe, Keizo, and Kojima, Seiji
- Subjects
- *
LEUKEMIA , *DOWN syndrome , *HUMAN chromosome abnormalities , *CYTOGENETICS , *MORPHOLOGY - Abstract
To characterize childhood acute megakaryoblastic leukaemia (AMKL), we reviewed 45 children with AMKL diagnosed between 1986 and 2005 at Nagoya University Hospital and Japanese Red Cross Nagoya First Hospital. Twenty-four patients (53%) had AMKL associated with Down syndrome (DS-AMKL) and 21 (47%) had non-DS-AMKL. The median age of the DS-AMKL patients was 21 months (range, 8–38 months) and that of non-DS-AMKL patients was 15 months (range, 2–185 months). The morphology of blast cells was categorized into three groups according to the stage of megakaryocyte maturation. The blast cells were more immature in DS-AMKL than in non-DS-AMKL in terms of morphology and immunophenotyping. Cytogenetic abnormalities of leukaemic cells were classified into seven categories: normal karyotype including constitutional trisomy 21 in DS-AMKL; numerical abnormalities only; t(1;22)(p13;q13); 3q21q26 abnormalities; t(16;21)(p11;q22); −5/del(5q) and/or −7/del(7q); and other structural changes. The outcome of children with either DS-AMKL or non-DS-AMKL is excellent. The 10-year overall survival estimate was 79% [95% confidence interval (CI): 54–90] for DS-AMKL and 76% (95% CI: 58–91) for non-DS-AMKL ( P = 0·81) with a median follow-up of 78 months (range, 20–243 months). Our study shows the diverse heterogeneity of childhood AMKL and the need for subclassification according to cytogenetic and morphological features. [ABSTRACT FROM AUTHOR]
- Published
- 2008
- Full Text
- View/download PDF
22. Preceding immunosuppressive therapy with antithymocyte globulin and ciclosporin increases the incidence of graft rejection in children with aplastic anaemia who underwent allogeneic bone marrow transplantation from HLA-identical siblings.
- Author
-
Kobayashi, Ryoji, Yabe, Hiromasa, Hara, Junichi, Morimoto, Akira, Tsuchida, Masahiro, Mugishima, Hideo, Ohara, Akira, Tsukimoto, Ichiro, Kato, Koji, Kigasawa, Hisato, Tabuchi, Ken, Nakahata, Tatsutoshi, Ohga, Shoichi, and Kojima, Seiji
- Subjects
- *
GRAFT rejection , *APLASTIC anemia , *BLOOD diseases , *BONE marrow transplantation , *IMMUNOSUPPRESSIVE agents , *LEUCOCYTES - Abstract
The incidence of graft rejection was determined in 66 children with acquired aplastic anaemia (AA) following bone marrow transplantation (BMT) from a related donor. Eleven of 65 evaluable patients experienced either early or late rejection. Multivariate analysis identified previous immunosuppressive therapy with antithymocyte-globulin (ATG) and ciclosporin (CsA) as a risk factor for graft rejection (relative risk: 16·6, P = 0·001). Patients who received ATG and CsA had a significantly lower probability of failure-free survival than those who did not (69·7 ± 6·2% vs. 87·9 ± 8·0%, P = 0·044). These results suggest that BMT should be instituted immediately in children with severe AA who have human leucocyte antigen-identical siblings. [ABSTRACT FROM AUTHOR]
- Published
- 2006
- Full Text
- View/download PDF
23. Human leucocyte antigen-Cw-specific cytotoxic T lymphocytes generated from naive cord blood used for cord blood stem cell transplantation.
- Author
-
Yazaki, Makoto, Takahashi, Toshitada, Mizutani, Keigo, Ito, Yasuhiko, Wakiguchi, Hiroshi, Inoue, Masami, Kawa, Keisei, Kato, Koji, Kato, Toro, Saito, Hidehiko, and Togari, Hajime
- Subjects
- *
STEM cells , *TRANSPLANTATION of organs, tissues, etc. , *LEUKEMIA - Abstract
Summary. Human leucocyte antigen (HLA)-Cw-reactive cytotoxic T lymphocytes (CTL) were generated from cord blood (CB) lymphocytes of two cases used for cord blood stem cell transplantation (CBSCT). In both cases, the CTL were cytotoxic against the patient's leukaemic cells, as well as the patient's Epstein–Barr virus (EBV)-lymphoblastoid cell line (EBV-LCL) and phytohaemagglutinin blasts, and the cytotoxicity was blocked by anti-HLA-class I monoclonal antibodies. In the first case, the CTL recognized Cw 3 (Cw 9 and Cw 10)-positive EBV-LCL, while in the second case, the CTL recognized Cw1 and/or Cw7. These cases suggest that CB T cells may be competent enough for generating CTL to induce a graft-versus-leukaemia effect and/or graft-versus-host disease in patients with CBSCT and that the mismatching of Cw antigens between patient and CB may be related to the outcome of CBSCT. [ABSTRACT FROM AUTHOR]
- Published
- 2002
- Full Text
- View/download PDF
24. Prospective monitoring of the Epstein–Barr virus DNA by a real-time quantitative polymerase chain reaction after allogenic stem cell transplantation.
- Author
-
Hoshino, Yo, Kimura, Hiroshi, Tanaka, Naoko, Tsuge, Ikuya, Kudo, Kazuko, Horibe, Keizo, Kato, Koji, Matsuyama, Takaharu, Kikuta, Atsushi, Kojima, Seiji, and Morishima, Tsuneo
- Subjects
- *
EPSTEIN-Barr virus diseases , *POLYMERASE chain reaction , *STEM cell transplantation , *GRAFT versus host disease , *PATIENTS - Abstract
Epstein-Barr virus (EBV)-related lymphoproliferative disorder (LPD) is a serious complication of haematopoietic stem cell transplantation (HSCT). To clarify the frequency, natural course and risk factors for LPD, we prospectively monitored 38 allogeneic (allo)-HSCT patients, focusing on the use of anti-thymocyte globulin (ATG). We used a recently developed real-time polymerase chain reaction assay to monitor EBV genome load. The subjects consisted of 19 patients given ATG for conditioning and 19 patients not given ATG. Of the 19 patients given ATG, 47·4% (nine patients) had a significant increase in EBV genome load (102·5 copies/µg DNA). Of these nine patients, two developed LPD. Therefore, 10·5% of the patients receiving allo-HSCT with ATG developed LPD. In contrast, none of the 19 patients without ATG had a significantly increased EBV load. The increases in viral load were observed in the second or third month after HSCT. We found that the peak viral loads of LPD patients were > 104·0 copies/µg DNA. On the other hand, the viral loads of most patients with no symptoms were < 102·5 copies/µg DNA. In conclusion, routine monitoring of EBV load during the second and third months after transplantation may benefit patients undergoing HSCT with ATG. We propose that an EBV load > 102·5 copies/µg DNA is the reactivation of EBV, and that an EBV load > 104·0 copies/µg DNA is indicative of developing LPD. [ABSTRACT FROM AUTHOR]
- Published
- 2001
- Full Text
- View/download PDF
25. Unrelated donor marrow transplantation in children with severe aplastic anaemia using cyclophosphamide, anti-thymocyte globulin and total body irradiation.
- Author
-
Kojima, Seiji, Inaba, Jun, Yoshimi, Ayami, Takahashi, Yoshiyuki, Watanabe, Nobuhiro, Kudo, Kazuko, Horibe, Keizo, Maeda, Naoko, Kato, Koji, and Matsuyama, Takaharu
- Subjects
- *
BONE marrow transplantation , *APLASTIC anemia treatment , *HLA histocompatibility antigens - Abstract
We report a favourable outcome in 15 patients with severe aplastic anaemia (SAA) who were < 20 years of age and who underwent bone marrow transplantation (BMT) from a human leucocyte antigen (HLA)-matched unrelated donor. All patients were non-responders to intensive immunosuppressive therapy (IST) and were multiply transfused. The conditioning regimen consisted of cyclophosphamide (60 mg/kg/d, on d -4 and -3), anti-thymocyte globulin (2·5 mg/kg/d, on d -5 to -2) and total body irradiation (2·5 Gy × 2/d, on d -2 and -1). Patients received cyclosporine and methotrexate for prophylaxis of graft-versus-host disease (GVHD), except for the last four who received tacrolimus instead of cyclosporine. Donor/recipient pairs were identical for HLA class I and II antigens by serological typing, but four pairs were found to have a mismatch at the HLA-A, -B or -DRB1 locus by high-resolution typing. All patients achieved rapid engraftment and are alive at 2–86 months after transplantation (median follow-up, 51 months). Moderate to severe acute GVHD occurred in 5 out of 15 patients (33%); only one patient developed extensive chronic GVHD. Considering our encouraging results, unrelated donor transplantation for SAA is recommended as a salvage therapy in non-responders to IST. [ABSTRACT FROM AUTHOR]
- Published
- 2001
- Full Text
- View/download PDF
26. Long-term outcome of acquired aplastic anaemia in children: comparison between immunosuppressive therapy and bone marrow transplantation.
- Author
-
Kojima, Seiji, Horibe, Keizo, Inaba, Jun, Yoshimi, Ayami, Takahashi, Yoshiyuki, Kudo, Kazuko, Kato, Koji, and Matsuyama, Takaharu
- Subjects
- *
APLASTIC anemia , *BONE marrow transplantation , *IMMUNOSUPPRESSIVE agents - Abstract
A total of 100 children under the age of 17 years with acquired aplastic anaemia (AA) were initially treated with immunosuppressive therapy (IST) (n = 63) or bone marrow transplantation (BMT) (n = 37) from an HLA-matched family donor. The projected 10-year survival rates were 55 ± 8% and 97 ± 3% respectively (P = 0·004). Because the IST group included 11 non-responders who were salvaged by BMT from an HLA-matched unrelated donor, we compared failure-free survival (FFS) between the groups. The probability of FFS at 10 years was 97 ± 3% for the BMT group, compared with 40 ± 8% for the IST group (P = 0·0001). Seven patients evolved to myelodysplastic syndrome (MDS) with monosomy 7 and the estimated cumulative incidence of MDS 10 years after diagnosis was 20 ± 7% in the IST group. We compared the outcome of children treated with IST during the two consecutive periods of 1983–91 (group A, n = 40) and 1991–8 (group B, n = 23) to assess the impact of combined therapy with anti-thymocyte globulin and cyclosporin. The probability of FFS at 7 years follow-up was the same in the two groups (50 ± 8% vs. 40 ± 15%, P = 0·40). We recommend BMT as first-line therapy in paediatric severe AA patients with an HLA-matched family donor. Alternative donor BMT is recommended as salvage therapy in patients who relapse or do not respond to initial IST. [ABSTRACT FROM AUTHOR]
- Published
- 2000
- Full Text
- View/download PDF
27. Successful treatment with low-dose gemtuzumab ozogamicin in combination chemotherapy followed by stem cell transplantation for children with refractory acute myeloid leukaemia.
- Author
-
Yoshida, Nao, Sakaguchi, Hirotoshi, Matsumoto, Kimikazu, and Kato, Koji
- Subjects
- *
ACUTE myeloid leukemia , *DRUG therapy , *STEM cell transplantation , *CALICHEAMICIN , *MONOCLONAL antibodies , *COMBINATION drug therapy - Abstract
The article focuses on a method developed to treat children with acute myeloid leukemia (AML) which consists of administering low-dose gemtuzumab ozogamicin (GO) in combination chemotherapy followed by stem cell transplantation. It adds that GO, a monoclonal anti-CD33 antibody conjugated with calicheamicin, is a promising agent for patients with AML who are resistant to conventional chemotherapy. It also talks about GO not being recommended as part of combination chemotherapy.
- Published
- 2012
- Full Text
- View/download PDF
28. Absence of mutations in the granulocyte colony-stimulating factor (G-CSF) receptor gene in patients with myelodysplastic syndrome/acute myeloblastic leukaemia occurring after treatment of aplastic anaemia with G-CSF.
- Author
-
Kudo, Kazuko, Nagai, Hirokazu, Numata, Shin-ichiro, Ichihara, Masatoshi, Kinoshita, Tomohiro, Horibe, Keizo, Kato, Koji, Matsuyama, Takaharu, Kodera, Yoshihisa, and Kojima, Seiji
- Subjects
- *
GRANULOCYTE-colony stimulating factor , *APLASTIC anemia treatment , *MYELODYSPLASTIC syndromes , *MYELOID leukemia , *THERAPEUTICS - Abstract
The development of myelodysplastic syndrome/acute myeloblastic leukaemia (MDS/AML) has been reported in patients with aplastic anaemia (AA) after administration of recombinant human granulocyte colony-stimulating factor (rhG-CSF). Similarly, patients with severe congenital neutropenia (SCN) have an increased risk of developing MDS/AML after treatment with rhG-CSF. Point mutations in the G-CSF receptor gene are found in about 20% of SCN patients who are predisposed to MDS/AML. We investigated the occurrence of mutations in the G-CSF receptor in eight patients with AA who developed MDS/AML. No mutations were detected around the cytoplasmic domain of the gene in our patients, indicating that the mechanisms of clonal evolution to MDS/AML in patients with AA might be different from those with SCN. [ABSTRACT FROM AUTHOR]
- Published
- 2000
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.